Galapagos Reconsiders Company Split After Market Developments

Galapagos, the Belgian biotech, has halted its planned split into two publicly traded entities:
one focused on drug development and the other on cell therapy operations123.

The decision to walk back the separation was announced on May 13, 2025, and follows recent regulatory and market developments23.

Originally, the split was set to complete by mid-2025, pending shareholder approval34.

The company will now re-evaluate its strategy and consider all strategic alternatives for its existing businesses, including the future of its cell therapy assets23.

Galapagos has appointed Henry Gosebruch as its new CEO, replacing Paul Stoffels, and Jérôme Contamine as Chair of the Board, signaling a leadership transition as part of the strategic update34.

The company stated it had made significant progress toward the split before deciding to re-examine its plans in light of the changing external environment34.

Sources:

1. https://pharmaphorum.com/news/galapagos-drops-plan-split-after-market-developments

2. https://firstwordpharma.com/story/5960106

3. https://www.nasdaq.com/articles/galapagos-re-evaluate-separation-plan-explore-alternatives-existing-businesses-names-ceo

4. https://www.globenewswire.com/news-release/2025/05/13/3079744/0/en/Galapagos-Announces-Strategic-Update-on-Proposed-Separation-Executive-Leadership-Transition-and-Board-Changes.html